Update on primary HIV-1 resistance in argentina:: Emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients

被引:32
作者
Petroni, Alejandro
Deluchi, Gabriel
Pryluka, Daniel
Rotryng, Flavio
Bortolozzi, Raul
Lopardo, Gustavo
Belen Bouzas, Maria
Zapiola, Ines
Garone, Daniela
Rodriguez, Claudia
Chiocconi, Eduardo
Esther Lazaro, Maria
Murano, Fernando
Maranzana, Aldo
Maris Oliva, Stella
Aparicio, Marta
Beltran, Marcelo
Benetucci, Jorge A.
机构
[1] FUNDAI, Hosp Muniz, Lab Retrovirus & Virus Asoc, RA-1282 Buenos Aires, DF, Argentina
[2] Ctr Med, Buenos Aires, DF, Argentina
[3] Hosp Juan Bautista Alberdi, Rosario, Santa Fe, Argentina
[4] Ctr Estudios Infectol, Buenos Aires, DF, Argentina
[5] Hosp Muniz, Unidad Virol, Buenos Aires, DF, Argentina
[6] Hosp Houssay, Buenos Aires, DF, Argentina
[7] Hosp Cosme Argerich, Buenos Aires, DF, Argentina
[8] Hosp Provincial Neuquen, Neuquen, Argentina
[9] Hosp Zonal, San Carlos De Bariloche, Rio Negro, Argentina
[10] Hosp Cordero, San Fernando, Buenos Aires, Argentina
[11] Hosp Artemides Zatti, Viedma, Rio Negro, Argentina
[12] Hosp Municipal San Isidro, Buenos Aires, DF, Argentina
关键词
HIV-1 primary resistance; B/F recombinant viruses; L89M; M41L; K103N; Argentina; BF RECOMBINANTS; BUENOS-AIRES; INDIVIDUALS; POPULATION; PREVALENCE; SUBTYPES;
D O I
10.1097/01.qai.0000222285.44460.e2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Here we present a survey including 52 drug-naive recently HIV-1-infected subjects from Buenos Aires City and province (79%) and 3 other regions in Argentina (21%). Recent infections were established from previous negative serology (32/52), indeterminate Western blot (12/52), or acute retroviral syndrome after high-risk HIV exposure (8/52) within 9 months before genotyping (median time, 4.2 months). Genotyping was performed from plasma by sequencing both protease and reverse transcriptase. Phylogenetic analysis combined with bootscanning resulted in 21 subtype B sequences and 31 B/F recombinants (RecBF). On protease, minor resistance-related mutations were found in both subtype B and RecBF with low frequencies. The substitution L89M, recently suggested as a resistance-related mutation in some subtype F viruses, was observed in I RecBF. On reverse transcriptase, major resistance-related mutations were found in 4 of 52 (7.7%) patients from different health centers: M41L (subtype B) and K103N +/- P225H (1 RecBF and 2 subtype B). The greater than 5% resistance threshold found indicates a need for sentinel resistance surveillances calling for an update in the current resistance testing guidelines in Argentina.
引用
收藏
页码:506 / 510
页数:5
相关论文
共 18 条
[11]  
*MIN SAL AMB NAC, 2005, B VIH SIDA ARG, V24
[12]  
PETRONI A, 2004, 11 C RETR OPP INF SA
[13]   HIV type 1 BF recombinant strains exhibit different pol gene mosaic patterns:: Descriptive analysis from 284 patients under treatment failure [J].
Quarleri, JF ;
Rubio, A ;
Carobene, M ;
Turk, G ;
Vignoles, M ;
Harrigan, RP ;
Montaner, JSG ;
Salomón, H ;
Gómez-Carrillo, M .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2004, 20 (10) :1100-1107
[14]   Primary HIV-1 drug resistance in Brazil [J].
Soares, MA ;
Brindeiro, RM ;
Tanuri, A .
AIDS, 2004, 18 :S9-S13
[15]   Widespread circulation of a B/F intersubtype recombinant form among HIV-1-infected individuals in Buenos Aires, Argentina [J].
Thomson, MM ;
Villahermosa, ML ;
Vázquez-de-Parga, E ;
Cuevas, MT ;
Delgado, E ;
Manjón, N ;
Medrano, L ;
Pérez-Alvareza, L ;
Contreras, G ;
Carrillo, MG ;
Salomón, H ;
Nájera, R .
AIDS, 2000, 14 (07) :897-899
[16]   Diversity of mosaic structures and common ancestry of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Argentina revealed by analysis of near full-length genome sequences [J].
Thomson, MM ;
Delgado, E ;
Herrero, I ;
Villahermosa, ML ;
Vázquez-de Parga, E ;
Cuevas, MT ;
Carmona, R ;
Medrano, L ;
Pérez-Alvarez, L ;
Cuevas, L ;
Nájera, R .
JOURNAL OF GENERAL VIROLOGY, 2002, 83 :107-119
[17]   The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities [J].
Weinstock, HS ;
Zaidi, I ;
Heneine, W ;
Bennett, D ;
Garcia-Lerma, JG ;
Douglas, JM ;
LaLota, M ;
Dickinson, G ;
Schwarcz, S ;
Torian, L ;
Wendell, D ;
Paul, S ;
Goza, GA ;
Ruiz, J ;
Boyett, B ;
Kaplan, JE .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (12) :2174-2180
[18]   Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe:: Implications for clinical management [J].
Wensing, AMJ ;
van de Vijver, DA ;
Angarano, G ;
Asjo, B ;
Balotta, C ;
Boeri, E ;
Camacho, R ;
Chaix, ML ;
Costagliola, D ;
De Luca, A ;
Derdelinckx, I ;
Grossman, Z ;
Hamouda, O ;
Hatzakis, A ;
Hemmer, R ;
Hoepelman, A ;
Horban, A ;
Korn, K ;
Kücherer, C ;
Leitner, T ;
Loveday, C ;
MacRae, E ;
Maljkovic, I ;
de Mendoza, C ;
Meyer, L ;
Nielsen, C ;
de Coul, ELO ;
Ormaasen, V ;
Paraskevis, D ;
Perrin, L ;
Puchhammer-Stockl, E ;
Ruiz, L ;
Salminen, M ;
Schmit, JC ;
Schneider, F ;
Schuurman, R ;
Soriano, V ;
Stanczak, G ;
Stanojevic, M ;
Vandamme, AM ;
Van Laethem, K ;
Violin, M ;
Wilbe, K ;
Yerly, S ;
Zazzi, M ;
Boucher, CA .
JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (06) :958-966